Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of MF59-adjuvanted Versus High-dose Influenza Vaccine in People With HIV
NCT07644546Not yet recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Sep 2026
- Primary completion
- Feb 2027
01
Overview
Randomised trial of influenza vaccine + MF59C.1 in influenza (3 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Vaccine response rate at 4 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
influenza vaccine + MF59C.1
03
Conditions
influenza
Beyond the preview
Go deeper on NCT07644546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07644546.